Follow-up: Immunogenicity according to reactogenicity of Covid-19 vaccines
- Conditions
- Reactogenicity and immunogenicity of Comirnaty
- Registration Number
- DRKS00026982
- Lead Sponsor
- niversity Medical Center Regensburg
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Enrolling by invitation
- Sex
- All
- Target Recruitment
- 76
Inclusion Criteria
immunoreakt study participants who were included in the final analysis of the immunoreakt study
Exclusion Criteria
1) new history of SARS-CoV-2 infection
2) new immunosuppression (disease or medication-induced)
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1) anti SARS-CoV-2 antibody course and neutralization activity 6 months (+- 4 weeks) after second vaccination with Comirnaty.<br><br>2) reactogenicity and immunogenicity of a third COVID-19 vaccination with an mRNA vaccine.
- Secondary Outcome Measures
Name Time Method Persistence of an immunological benefit of men with severe adverse reactions after first and/or second vaccination with Comirnaty compared to men without adverse reactions after first and second vaccination.